Valneva reported preliminary unaudited FY 2025 total revenues of EUR 174.7 million, including product sales of EUR 157.9 million (-3.3%). Third-party product sales were EUR 19.2 million (-42.3%). Cash and cash equivalents were EUR 109.7 million at December 31, 2025. For FY 2026, Valneva guided total revenues of EUR 155-170 million, including product sales of EUR 145-160 million, citing continued growth of its established commercial brands offset by the wind-down of third-party sales. The company said the first Phase 3 data readout for its Lyme disease vaccine candidate is expected in H1 2026, with regulatory submissions expected to follow as planned by Pfizer subject to positive results, and that first Phase 2 data for its tetravalent shigella vaccine candidate S4V2 are expected with a decision on subsequent development steps anticipated in H2 2026. Valneva also said its CEO’s contract was renewed for a further three-year term, subject to approval at the 2026 AGM.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valneva SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001165485-en) on February 19, 2026, and is solely responsible for the information contained therein.